PMID- 27048192
OWN - NLM
STAT- MEDLINE
DCOM- 20180920
LR  - 20180920
IS  - 2212-3911 (Electronic)
IS  - 1574-8863 (Linking)
VI  - 13
IP  - 1
DP  - 2018
TI  - Generalized Intense Pruritus During Canagliflozin Treatment: Is it an Adverse 
      Drug Reaction?
PG  - 38-40
LID - 10.2174/1574886311666160405110515 [doi]
AB  - BACKGROUND: Selective agents able to locate and identify unique targets represent 
      a crucial aspect of modern pharmacology. The exclusive location of Sodium-Glucose 
      co-Transporter-2 (SGLUT2) on kidneys prompt companies to develop SGLT2 inhibitors 
      that today are the latest class of drugs for diabetes treatment. In particular, 
      canagliflozin blocks the re-absorption of glucose in the kidney lowering blood 
      glucose levels by increasing glucose excretion. CASE DESCRIPTION: We report a 
      61-year old woman who developed an intense and severe pruritus during the 
      treatment with canagliflozin. Clinical and laboratory findings excluded the 
      presence of systemic or skin diseases able to induce pruritus. The 
      discontinuation of canagliflozin and the treatment with pioglitazone/metformin 
      fixed combination induced a remission of pruritus. CONCLUSION: This case 
      emphasizes the need to consider pruritus as a differential diagnosis during the 
      treatment with canagliflozin.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Vasapollo, Piero
AU  - Vasapollo P
AD  - Department of General and Territorial Medicine, Azienda Sanitaria Provinciale, 
      Crotone, Italy.
FAU - Cione, Erika
AU  - Cione E
AD  - Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 
      Catanzaro, Italy.
FAU - Luciani, Filippo
AU  - Luciani F
AD  - Infectious Disease Unit, Annunziata Hospital, Cosenza, Italy.
FAU - Gallelli, Luca
AU  - Gallelli L
AD  - Department of Health Science, University of Catanzaro and Operative Unit of 
      Clinical Pharmacology and Pharmacovigilance, Mater Domini Hospital, Catanzaro, 
      Italy.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Drug Saf
JT  - Current drug safety
JID - 101270895
RN  - 0 (Hypoglycemic Agents)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Canagliflozin/*adverse effects
MH  - Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Drug-Related Side Effects and Adverse Reactions/*diagnosis
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects
MH  - Middle Aged
MH  - Pruritus/*chemically induced/*diagnosis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Pruritus
OT  - SGLT2
OT  - adverse drug reaction
OT  - canagliflozin
OT  - pharmacology
OT  - sodium-glucose.
EDAT- 2016/04/07 06:00
MHDA- 2018/09/21 06:00
CRDT- 2016/04/07 06:00
PHST- 2016/01/15 00:00 [received]
PHST- 2016/03/16 00:00 [revised]
PHST- 2016/04/01 00:00 [accepted]
PHST- 2016/04/07 06:00 [pubmed]
PHST- 2018/09/21 06:00 [medline]
PHST- 2016/04/07 06:00 [entrez]
AID - CDS-EPUB-74798 [pii]
AID - 10.2174/1574886311666160405110515 [doi]
PST - ppublish
SO  - Curr Drug Saf. 2018;13(1):38-40. doi: 10.2174/1574886311666160405110515.